Olaparib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 3837 publications

Integrating Machine Learning and Structure-Guided Discovery of a Novel Type II SYK Inhibitor for Treating Triple-Negative Breast Cancer.

Integrating Machine Learning and Structure-Guided Discovery of a Novel Type II SYK Inhibitor for Treating Triple-Negative Breast Cancer.

Journal: Journal of medicinal chemistry

Published: June 17, 2026

Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.

Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions.

Journal: Clinical advances in hematology & oncology : H&O

Published: June 12, 2026

Synthesis and Preliminary Evaluation of the 211At-Labeled PARP Inhibitor [211At]Talazoparib as a Targeted Alpha-Particle Emitting Therapeutic.

Synthesis and Preliminary Evaluation of the 211At-Labeled PARP Inhibitor [211At]Talazoparib as a Targeted Alpha-Particle Emitting Therapeutic.

Journal: Molecular pharmaceutics

Published: June 08, 2026

STN1 upregulation promotes PARPi resistance in BRCA2-deficient cancer cells via replication fork protection and suppression of ssDNA gap formation.

STN1 upregulation promotes PARPi resistance in BRCA2-deficient cancer cells via replication fork protection and suppression of ssDNA gap formation.

Journal: bioRxiv : the preprint server for biology

Published: June 04, 2026

Manganese Oxide-Based Multifunctional Nanoplatform for Synergistic Therapy of Triple-Negative Breast Cancer.

Manganese Oxide-Based Multifunctional Nanoplatform for Synergistic Therapy of Triple-Negative Breast Cancer.

Journal: ACS applied bio materials

Published: June 04, 2026

Targeting lactate with a GLUT1 inhibitor reverses PARP inhibitor resistance in ovarian cancer.

Targeting lactate with a GLUT1 inhibitor reverses PARP inhibitor resistance in ovarian cancer.

Journal: Acta biochimica et biophysica Sinica

Published: May 29, 2026

A CASE OF CASTRATION-RESISTANT PROSTATE CANCER ASSOCIATED WITH HEREDITARY BREAST-OVARIAN CANCER SYNDROME SHOWING LONG-TERM RESPONSE TO A POLY-ADP RIBOSE POLYMERASE INHIBITOR

A CASE OF CASTRATION-RESISTANT PROSTATE CANCER ASSOCIATED WITH HEREDITARY BREAST-OVARIAN CANCER SYNDROME SHOWING LONG-TERM RESPONSE TO A POLY-ADP RIBOSE POLYMERASE INHIBITOR

Journal: Hinyokika kiyo. Acta urologica Japonica

Published: May 26, 2026

Adjuvant olaparib real world data for BRCA positive, HER2-negative high-risk early breast cancer patients in the United Kingdom.

Adjuvant olaparib real world data for BRCA positive, HER2-negative high-risk early breast cancer patients in the United Kingdom.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: May 25, 2026

Re: Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men with Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE).

Re: Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men with Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE).

Journal: European urology

Published: May 22, 2026

PARP1 rewires neuroinflammatory and redox metabolism associated with reactive neuroglia in neuropathic pain.

PARP1 rewires neuroinflammatory and redox metabolism associated with reactive neuroglia in neuropathic pain.

Journal: Redox biology

Published: May 20, 2026

Pan-Cancer Landscape of Thymine DNA Glycosylase and Its Potential Role in Lung Adenocarcinoma.

Pan-Cancer Landscape of Thymine DNA Glycosylase and Its Potential Role in Lung Adenocarcinoma.

Journal: Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae

Published: May 15, 2026

Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial.

Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial.

Journal: JCO precision oncology

Published: May 11, 2026

Showing 1-12 of 3,837

Last Updated: 06/30/2026